Compare Tempus AI (TEM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tempus AI vs Twist Bioscience Corp — how do they compare? Tempus AI trades at $60.44 (market cap $11.13B), while Twist Bioscience Corp trades at $125.52 (market cap $8.26B). The key difference: Tempus AI is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals.
| TEM | TWST | |
|---|---|---|
Market Cap | $11.13B | $8.26B |
Sector | Broad Market / Factor | Health |
52-Week High | $103.25 | $153.10 |
52-Week Low | $41.55 | $24.16 |
Enterprise Value | $11.75B | $8.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tempus AI (TEM) trades at $64.29, down 0.51% on the day, with a bullish technical signal from moving averages and RSI near oversold levels. The company reported a net loss of $245.03M in 2025 despite revenue of $1.27B, but recent quarterly EPS beats and FDA clearance for an AI-enabled ECG product (Business Wire, 2026-08-24) highlight growth potential in precision medicine. Analyst consensus is strongly bullish with a $69.20 price target.
Outlook: TEM's AI-driven healthcare platform positions it for long-term growth amid industry shifts toward personalized medicine, though persistent losses and high P/B of 25.01 pose valuation risks. Near-term catalysts include continued execution on recent contracts and pipeline developments, but investors face volatility from cash burn and competitive pressures.
Twist Bioscience (TWST) trades at $128.06, up 2.68% with a bearish technical signal despite recent AI-driven momentum. The company shows strong revenue growth (2025: $377M, 2026: $432M projected) but continues to report significant losses with negative net margins. Recent news highlights AI partnerships and a $300M stock offering, while analyst consensus remains predominantly bullish with 78.6% buy ratings.
TWST presents a high-risk growth opportunity with accelerating revenue but persistent profitability challenges. The stock's valuation appears stretched at P/S of 18.09, requiring successful execution on AI initiatives and path to EBITDA breakeven. Key risks include cash burn, competitive pressures, and dependence on emerging AI-driven drug discovery markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
